GEXVal Inc.
February 21, 2025

Series C Extension Round Completed: Achieved Total Series C Funding of JPY 910 Million

GEXVal Inc. (President & CEO Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) announces that it has raised JPY 50 million through a third-party allotment of shares from a business corporation as part of its Series C extension round (hereinafter “this capital increase”). With this funding, our company has successfully reached our Series C target, completing the round with JPY 910 million. This funding will accelerate the clinical development and enhance the value of GXV-001⁽¹⁾ while strengthening our business operations.

GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology (RePhaIND®⁽²⁾), we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

(1) About GXV-001:
GXV-001 has completed Phase I clinical trials and Proof of Mechanism* studies through our wholly owned subsidiary, GEXVal AU Pty Ltd. We are currently preparing for Phase II clinical trials as a clinical development program for neurological disorders.
* Proof of Mechanism (POM): In clinical trials, this refers to "proof of mechanism of action," which verifies that the drug exerts pharmacological effects on the intended target molecule and induces physiological responses.

(2) About RePhaIND®:
Powered by RePhaIND® - EMPOWER・ACCELERATE・REVOLUTIONIZE Drug Discovery
RePhaIND® is GEXVal's proprietary AI-driven drug discovery platform powered by Graph Attention Autoencoding (GATE)-a state-of-the-art neural network architecture that analyzes complex biological relationships in a multimodal approach. This innovative platform offers three key features:

• EMPOWER: Discover hidden relationships between drug candidates and diseases
• ACCELERATE: Dramatically improve efficiency compared to conventional methods　
• REVOLUTIONIZE: Enable new approaches to unmet medical needs, particularly in rare diseases, bringing a paradigm shift to the drug discovery process

For further information:
Head of Corporate office
Atsushi Sugizaki
info@gexval.com